Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Thomas M. who wrote (911)	6/20/1998 10:38:00 AM
From: Ed Ajootian	Read Replies (2) \| Respond to of 10280

Tom, I really haven't heard anything implying an imminent FDA action on levalbuterol. In fact, the clues are that it will not be for at least several more months. Sturza's latest fax updates SEPR and says that he expects the FDA to approve levalbuterol "by August". Since he is usually a bit premature in his projections of future FDA actions I would not be at all surprised if the actual event does not occur until the fall. One thing that will probably come before the levalbuterol news is the Oxybutynin Phase II study news. He says they plan to complete the study this month. Since they are looking for a collaborator to take this drug further I would think that they would want to release the study results as soon as possible. Sturza has cooled a bit on SEPR. It's weird -- he still says its a "Strong BUY", yet then he says to buy on weakness under $40. One would think if it were that great a stock he would be saying to load up even at $42, a mere 5% higher quote.